← Back to list
Dendritic Cell Immunotherapy (CPB 0377, reviewed 2026-05-26)
Effective date
Not stated in the notice
Identified
Aug 14, 2026
Summary
Aetna considers dendritic cell immunotherapy experimental, investigational, or unproven because the peer-reviewed medical literature does not support its clinical use at this time, and there is no specific CPT or HCPCS code for it. ICD-10 codes for malignant neoplasms (leukemia, lymphoma, melanoma and solid tumors) and for melanoma in situ are listed as not covered for the indications in this bulletin. Current evidence is described as anecdotal, and randomized trials are needed to establish the appropriate antigen, adjuvant, dose, route and schedule.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.
Get Aetna alertsPolicy Monitoring is free. No card required.
What to do
Action · 2 steps
01Billing team: Do not bill dendritic cell immunotherapy as a covered service, because Aetna considers it experimental, investigational or unproven.
02Billing team: Treat the ICD-10 malignant neoplasm codes and melanoma in situ codes listed in this bulletin as not covered for dendritic cell immunotherapy.
Codes mentioned
C00.0C43.9C44.00C75.9C76.0C86.61C88.40C94.32C94.80C96.4C96.6C96.9D03.0D03.9
Original notice
Dendritic Cell Immunotherapy (CPB 0377, reviewed 2026-05-26)
aetna.com · Always check the source before changing claims.
Related changes
See all Aetna changes →Zoledronic Acid (CPB 0524, reviewed 2026-02-12)MediumNo effective date · Medical PolicyPlerixafor (CPB 0779, reviewed 2026-02-13)MediumNo effective date · Medical PolicyPaclitaxel, Albumin-Bound (CPB 0834, reviewed 2026-05-28)MediumNo effective date · Medical PolicyLiver and Other Neoplasms - Treatment Approaches (CPB 0268, reviewed 2026-09-18)MediumNo effective date · Medical PolicyBrowse every Aetna change in the policy list